Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Guides On Rivals To Primatene Mist And Spiriva Respimat

Agency Releases Batch Of 34 Product-Specific Guidances

Executive Summary

A batch of almost three dozen new and revised product-specific guidances for generic products has been published by the US Food and Drug Administration, including for rivals to Primatene Mist (epinephrine) metered-dose inhaler and Spiriva Respimat (tiotropium bromide) inhalation spray.

You may also be interested in...



ANI To Divest Two And Agree To Other Provisions To Close Novitium Deal

Before closing its acquisition of fellow US-based manufacturer Novitium Pharma, ANI Pharmaceuticals must agree to several orders, including divestment of rights and/or assets for two generic products.

FDA Grant Establishes Complex Generics Center To Increase Access

Complex active ingredients, formulations, routes of delivery, and drug-device combination products are to receive greater attention as part of attempts to facilitate competition after the US FDA awarded a $5m grant to establish a dedicated research center.

AMR Industry Alliance Publishes Manufacturing Standard

The AMR Industry Alliance has formalized its years-old Common Antibiotic Manufacturing Framework by publishing an antibiotic manufacturing standard, in what it terms a “groundbreaking step” in the drive for responsible manufacturing.

Topics

Latest News
UsernamePublicRestriction

Register

GB150446

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel